On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

A woman on Ozempic has revealed why she gave her 11 year old daughter weight loss jabs, a similar drug called Wegovy, on This Morning ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

A MOTHER who put her daughter on weight loss jabs at the age of 11 has opened up on her family’s experience with the ...

We can't have it both ways. If we want more cutting-edge drugs, we have to protect the property rights that make them ...

Hims & Hers Health recurring revenue grew 111% YoY, boosted by personalization and chronic care. Forecasting $2.35B revenue ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

It’s a controversial topic… Should we give weight-loss jabs to kids? Over in America, we meet mum Ashley Hamilton, who’s allowed her daughter, Sophia, to use Wegovy since she was just 11 years old.

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

Experts say there’s no evidence GLP-1s can be absorbed through the skin — and these patches don’t contain the FDA-approved ...